NASD · Healthcare · Biotechnology · USA
Immunome Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Immunome is a biotechnology company developing targeted oncology therapies, primarily antibody-drug conjugates and other cancer treatments. The company has three clinical assets under evaluation, including varegacestat for desmoid tumors, IM-1021 for B-cell lymphoma, and IM-3050 for solid tumors, along with three preclinical assets in its pipeline.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Immunome Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
129 more in this industry show a wider margin of safety.
We do not publish a verdict on IMNM yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.